(Q35178040)

7 August 2017

Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice (English)

1 reference

7 August 2017

1 reference

1 reference

T Buckle

2

0 references

Jos Beijnen

5

object named as

J H Beijnen

1 reference

7 August 2017

Roos L Oostendorp

1

1 reference

7 August 2017

G Lambert

3

1 reference

7 August 2017

J S Garrigue

4

1 reference

7 August 2017

J H M Schellens

6

1 reference

7 August 2017

O van Tellingen

7

1 reference

7 August 2017

13 April 2010

1 reference

Investigational New Drugs

7 August 2017

1 reference

7 August 2017

29

1 reference

7 August 2017

5

1 reference

7 August 2017

768-776

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-010-9421-7

7 August 2017

0 references

cites work

A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160553

Excipient effects on in vitro cytotoxicity of a novel paclitaxel self‐emulsifying drug delivery system

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160553

The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160553

Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160553

Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160553

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160553

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160553

Patient preferences for oral versus intravenous palliative chemotherapy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160553

Pharmacology and toxicology of Cremophor EL diluent

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160553

Clinical pharmacology and metabolism of Taxol (paclitaxel): update 1993.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160553

Taxanes: a new class of antitumor agents.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160553

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients

28 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9421-7

Modulation of oral bioavailability of anticancer drugs: from mouse to man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9421-7

Anaemia after enalapril in a child with nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9421-7

Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9421-7

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9421-7

Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9421-7

The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9421-7

Variability in human cytochrome P450 paclitaxel metabolism

21 January 2018

1 reference

12 December 2020

Phase I and pharmacokinetic study of oral paclitaxel

1 reference

12 December 2020

Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Use of water-soluble liquid vitamin E to enhance cyclosporine absorption in children after liver transplant

1 reference

12 December 2020

Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A

1 reference

12 December 2020

Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography

1 reference

12 December 2020

Co-administration of cyclosporin enables oral therapy with paclitaxel

1 reference

12 December 2020

Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL

1 reference

12 December 2020

Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography

1 reference

12 December 2020

10.1007/S10637-010-9421-7

Identifiers

DOI

1 reference

7 August 2017

1 reference

7 August 2017

1 reference